MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.2610
+0.0098
+3.90%
After Hours: 0.2630 +0.002 +0.77% 19:40 02/21 EST
OPEN
0.2680
PREV CLOSE
0.2512
HIGH
0.2870
LOW
0.2550
VOLUME
6.67M
TURNOVER
--
52 WEEK HIGH
0.7085
52 WEEK LOW
0.1900
MARKET CAP
42.85M
P/E (TTM)
-1.4737
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ATNM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATNM stock price target is 2.750 with a high estimate of 4.000 and a low estimate of 1.500.

EPS

ATNM News

More
  • Actinium Pharma up 17% premarket on encouraging Iomab-B data
  • Seeking Alpha - Article · 1d ago
  • Actinium Highlights Presentation Of Findings From Mid-Point Analysis Of Pivotal SIERRA Trial Of Iomab-B At 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
  • Benzinga · 1d ago
  • Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)
  • PR Newswire · 1d ago
  • Actinium Pharmaceuticals (ATNM) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 02/13 17:29

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ATNM

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
More

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.